End-stage kidney disease patients treated with automated peritoneal dialysis (APD) Urological and Genital Diseases Chronic kidney disease, stage 5
Conditions
Interventions
We used a purposive sampling method to enroll study participants in the outpatient department. After the study protocol was explained and informed consent was obtained, we used a computer-generated bl
Sponsors
Baxter
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Agreed to receive nocturnal APD regimen with daytime dwell of at least 10 h
Exclusion criteria
Exclusion criteria: 1. Starch allergy 2. Glycogen storage disease 3. Life expectancy of <12 months 4. Serious disease within 30 days before randomization 5. Pregnancy or lactation 6. Significant psychiatric disorder that would interfere with their ability to provide informed consent and/or comply with the study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac structure and function are measured using echocardiography at baseline, 1 year and 2 years. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization for heart failure in the study period measured by patient medical records review. | — |
Countries
Taiwan
Outcome results
None listed